The NE Journal Medicine Medicine publishes promising Alzheimer’s treatment studies

U.S. New drugs for Alzheimer’s have not been approved by the Food and Drug Administration since 2003, but a new study published by THe started the New England Journal of Medicine Saturday is showing optimistic preliminary results.

Donanemabe, antibody treatment produced by drug manufacturer Eli Lilly and company, targeted a. Improved form of amyloid-β (Aβ) peptide – Plaque Which accumulates in the minds of the people With Alzheimer’s. Clinical trials at an early stage Results Showed that at 52 weeks, people receiving the experimental drug achieved a negative status at amyloid plaque levels. In other words, the level of amyloid plaque was about the same as that of the average person.

To establish the study, half of the 275 patients who participated received the drug as part of a trial for 76 weeks, while the other half received a placebo. Those involved were people with people Early therapeutic Alzheimer’s disease.

“We believe in the results of the Trailblazer-ALZ study,” said Daniel Schwronski, Lily’s chief scientific officer and chairman of Lily Research Laboratories. Statement. “This is an early-stage study of Alzheimer’s disease, which completes its primary endpoint in the primary analysis. Donanemb is likely to be a very important treatment for Alzheimer’s disease.”

By observing memory and the ability to perform daily tasks, the researchers also found that the drug slows cognitive decline by about 32%.

Overall, approximately 40% of participants achieved amyloid negativity within six months of starting treatment, and 68% reached this goal at 18 months.

“We were pleased to see not only a slowing of cognitive and functional decline, but also a very significant clearance of amyloid plaques and a slowdown in the spread of pathology,” said Schwronski. “The constellation of clinical and biomarker outcomes indicates the potential for change in long-term disease. We are grateful to the patients, carers and investigators who participated in this landmark study. “

Although the results are promising, researchers say longer and more detailed tests are still needed to ensure donanemab safety.

According to Centers for Disease Control and Prevention, Alzheimer’s in the U.S. Is one of the top 10 leading causes of death in, and the fifth leading cause of death among adults 65 or older.

The FDA is also currently reviewing others, Separate experimental medicine From Biogen, a Cambridge based company and the Japanese Spouse Isai Co.

Only a few medications are approved to manage the symptoms of Alzheimer’s, and there is no cure for it.